American Journal of Cardiovascular Drugs

Papers
(The TQCC of American Journal of Cardiovascular Drugs is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Authors’ Reply to Rangwala et al: “Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis”89
The Use of Drugs that Should be Avoided or Used with Caution in Patients Hospitalized for Acute Decompensated Heart Failure49
Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy46
Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis33
Authors’ Reply to Khan et al. “Evaluating the Effectiveness and Safety of Evinacumab in Treating Hypercholesterolemia and Hypertriglyceridemia: A Systematic Review and Meta-analysis of Randomized Cont33
Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review31
Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly26
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country22
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis20
Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects19
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study19
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome17
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects17
Comment on: "A Retrospective Cohort Study on Long‑Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion"17
Efficacy and Safety of Alprostadil in Microcirculatory Disturbances During Emergency PCI: A Meta-Analysis of Randomized Controlled Trials17
Administration of Evolocumab in Patients with STEMI After Emergency PCI: A Real-World Cohort Study17
Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy Participants15
Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Placebo-Controlled Trials14
Author’s Reply to: “Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide”14
Efficacy and Safety of Ongericimab in Chinese Patients with Hypercholesterolemia: A Meta-analysis of Randomized Controlled Trials14
SGLT2 Inhibitors and Improved Survival in Patients with Diabetes and Acute Myocardial Infarction: Evidence from an Electronic Health Record-Based Cohort Study14
Flurpiridaz F 18: First Approval14
Impact of Newly Diagnosed Cancer on Bleeding Events in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants13
A Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients13
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis13
Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 202012
Rhythm, Risk, and Responsibility: Assessing the Safety of Testosterone Replacement in Aging Men with Androgen Deficiency12
Geographic and Racial Variation in Oral Anticoagulant (OAC) Treatment Among Commercially Insured Patients with Non-valvular Atrial Fibrillation (NVAF) in the United States12
Acknowledgement to Referees12
Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits11
Morphine and P2Y12 Inhibitors in ST-Elevation Myocardial Infarction: An Updated Meta-Analysis11
Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future11
Adenosine Administration in Supraventricular Tachycardia: Single- or Double-Syringe Technique?11
Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands11
Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure10
Characteristics and Impact of Randomized Trials on Drugs or Devices in Cardiovascular Medicine10
Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?10
BCAA Metabolic Dyshomeostasis in Cardiovascular Disease: Pathogenic Mechanisms and Intervention10
Author’s Reply to Freund and Gorlicki: “Door-to-Diuretic Time and Outcomes in Acute Heart Failure: A Scoping Review”10
Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction: A Meta-Analysis of Kaplan–Meier Reconstructed Individual Patient Data10
Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial10
The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis9
Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial8
One-Year Prognostic Differences and Management Strategies between ST-Elevation and Non-ST-Elevation Myocardial Infarction: Insights from the PRAISE Registry8
An Updated Review of Novel Triglyceride-Lowering Therapies in Adults with Familial Chylomicronemia Syndrome8
A Meeting Report from the 74th Annual Scientific Sessions of the American College of Cardiology: March 29–31, 2025; Chicago, IL, USA8
The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?8
Long-Term Effects of Low-Dose Aspirin on Gastrointestinal Symptoms and Bleeding Complications in Patients with Type 2 Diabetes8
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications8
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States8
Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies8
Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile7
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease7
Exercise Training Enhances Brachial Artery Endothelial Function, Possibly via Improved HDL-C, not LDL-C and TG, in Patients with Coronary Artery Disease: A Systematic Review and Meta-analysis7
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction7
Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations7
Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”7
Chronotherapy for Hypertension: A Meta-Analysis and Systematic Review of RCTs6
Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Up6
Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease6
Safety and Efficacy of DOAC Versus VKA in Adult Congenital Heart Disease: A Systematic Review and Meta-Analysis6
Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat6
Risk of Hematuria, Proteinuria, and Cardiovascular Events in Patients Treated with Rosuvastatin Compared with Atorvastatin: A Retrospective Cohort Study in 136,680 Patients6
Double Trouble: The Challenge of Neuroprotection in Patients with Liver Cirrhosis and Atrial Fibrillation6
A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten6
Overview of Systematic Reviews on Treatments for Pulmonary Arterial Hypertension: Assessing Methodological Quality and Mapping Evidence Gaps6
Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter6
0.67685413360596